As with any medicine, the MHRA will keep the safety and effectiveness of imlunestrant tosylate under close review.
Similar Posts
Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure
This is a precautionary measure while the MHRA conducts the safety review.
Field Safety Notices: 10 to 14 November 2025
List of Field Safety Notices from 10 to 14 November 2025.
Guidance: Health Institution Exemption for general medical devices
Guidance for health institutions that manufacture general medical devices under the Health Institution Exemption (HIE).
Medicines: get scientific advice from MHRA
A summary of the types of scientific advice available at the MHRA, the process for getting advice and the fees involved.
Medical devices: get regulatory advice from the MHRA
How to apply for a regulatory advice meeting on medical devices and in vitro diagnostic devices.
Medicines: apply for a variation to your marketing authorisation
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.